Recruiting PHASE1, PHASE2 Tetanus-diphtheria-acellular Pertussis (Tdap)

Tests treatment safety and results for Tetanus-diphtheria-acellular Pertussis (Tdap)

Official title A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults

ClinicalTrials.gov ID: NCT06997627

What this study is testing

What is GC3111B?

GC3111B is an investigational medicine, given as an injection into a muscle, being studied as a potential treatment for tetanus-diphtheria-acellular pertussis (tdap).

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
This clinical trial consists of two parts: Part 1, which explores safety, and Part 2, which examines both safety and efficacy (immunogenicity). Part 1 is a single-center, open-label, single-group study, while Part 2 is designed as a multicenter, double-blind, randomized, active-controlled trial.
  • Phase 2: a mid-size study of how well it works
  • Which group you join is decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 19 to 64. Healthy volunteers may be eligible.

You may be able to join if

  • Healthy adults aged 19 to 64 years old as of the date of written consent.
  • Individuals with no history of vaccination with a vaccine containing diphtheria, tetanus, or pertussis antigens within the past 2 years prior to...

You likely can't join if

  • Individuals who have received a vaccine within 4 weeks prior to administration of the investigational product.
  • Individuals with a history of Tdap vaccination prior to administration of the investigational product.
  • Pregnant and breastfeeding women.
  • Individuals who have participated in other clinical trials involving investigational products/devices within 6 months prior to administration of the...

The study team makes the final eligibility decision.

Where it's taking place

  • Seoul, South Korea

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 19 years to 64 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Seoul, South Korea. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.